Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers identified novel long non-coding RNAs related to cashmere fineness in goats, highlighting a potential regulatory network involving lncRNA XLOC_008679 and its target gene KRT35.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This research reports a new autosomal recessive mutation in mice, 'lanceolate hair', causing generalized alopecia and hair shaft abnormalities, which may serve as a model for Netherton's syndrome in humans.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study found that ion-paired solutions significantly improved the skin penetration of risedronate in hairless mice compared to risedronate alone.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This study found that certain lncRNA gene polymorphisms in HOTAIR and MALAT1 are associated with increased susceptibility to systemic lupus erythematosus, potentially informing clinical applications.

This review explores clinical studies on low-level laser therapy (LLLT) for alopecia and suggests it may benefit patients unresponsive to conventional treatments, but larger studies are needed to confirm efficacy.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

This study identified a mutant in Arabidopsis with shorter root hairs due to early growth cessation, implicating the IRE gene in regulating root hair growth duration.

LIPH mutations cause woolly hair in some Chinese people.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

In this study, researchers observed that knocking down the LPA 4 receptor in zebrafish embryos led to vascular and lymph vessel development abnormalities, including edema and decreased heartbeats.

In this pilot study, PDLLA scalp microinjections showed improvement in physician-rated Global Aesthetic Improvement Scale scores over 12-24 weeks for 90% of patients with non-scarring alopecia, with no serious adverse events reported, although findings remain preliminary due to methodological limitations.

This review found that laser-assisted drug delivery in humans was associated with several adverse effects, but no life-threatening events were reported in the studies examined.

This report presents the early development of the Lupus Foundation of America's LFA-REAL™ patient-reported instrument, designed to enhance evaluation of lupus disease activity by combining patient and physician assessments.

This study identified a novel mutation and confirmed a previous mutation in the LIPH gene in a woman with autosomal recessive woolly hair, expanding the mutation spectrum for this condition.

In this study, researchers reported that treating alopecia areata patients with ritlecitinib led to progressive improvements in emotional symptoms and activity limitations over 48 weeks, though the post hoc analysis and trial setting suggest caution in interpreting the findings for broader populations.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This narrative review discusses the role and importance of rheumatologists in managing autoimmune interstitial lung disease and emphasizes the need for enhanced collaboration with respiratory physicians to improve diagnosis, management, and outcomes; no new clinical results are reported.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.

This review highlights the emerging role of long non-coding RNAs (lncRNAs) in dermatology, suggesting that lncRNAs significantly impact signaling pathways involved in normal skin functions and skin diseases, offering potential as biomarkers and therapeutic targets.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This study introduced rPanglaoDB, an R package that facilitates the integration of public scRNA-seq datasets to effectively characterize rare cell types, exemplified by generating the first unbiased transcriptome profile of fibrocytes.

This study found that low-level laser therapy effectively reduced relapse rates, while functional appliances did not; combining them offered no additional benefits.